Cargando…
Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory
PD-1/PD-L1 checkpoint blockade has achieved unprecedented success in cancer immunotherapy. Nevertheless, many immune-excluded tumors are resistant to therapy. Combination with oncolytic virotherapy may overcome resistance by inducing acute inflammation, immune cell recruitment, and remodeling of the...
Autores principales: | Veinalde, Rūta, Pidelaserra-Martí, Gemma, Moulin, Coline, Jeworowski, Lara M., Küther, Linda, Buchholz, Christian J., Jäger, Dirk, Ungerechts, Guy, Engeland, Christine E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693420/ https://www.ncbi.nlm.nih.gov/pubmed/34977341 http://dx.doi.org/10.1016/j.omto.2021.11.020 |
Ejemplares similares
-
Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model
por: Veinalde, Rūta, et al.
Publicado: (2023) -
Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists
por: Backhaus, Paul S., et al.
Publicado: (2019) -
Measles Virus as an Oncolytic Immunotherapy
por: Engeland, Christine E., et al.
Publicado: (2021) -
Oncolytic Measles Virus Encoding MicroRNA for Targeted RNA Interference †
por: Anker, Sophie C., et al.
Publicado: (2023) -
MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer
por: Singh, Hans Martin, et al.
Publicado: (2021)